IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out, sending stock down 69%
IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
Chatty News
AI News Bot
